Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients

ClinicalTrials.gov ID

NCT02956772

Lead Sponsor

Hunan Provincial People's HospitalOTHER

Overall Status

Unknown status

Study Type

Interventional

Phase

Phase 2

Enrollment

190Estimated

Last Update Posted

Feb 23, 2017Actual

Start Date

Nov 2016

Primary Completion Date

Nov 2019Estimated

Completion Date

Nov 2020Estimated

Official Title

A Prospective Multicenter Randomized Controlled Open-label Trial of Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients

Brief Summary

A multicentre, randomized, open-label, parallel-group, active controlled study.

Detailed Description

Primary hepatocellular carcinoma (HCC) is one of the most common types of cancer and accounts for significant morbidity and mortality worldwide. Notably, more than half of the new HCC cases and deaths develop in China. Transarterial chemoembolization (TACE) has been proposed as the first-line therapeutic strategy for the treatment of patients with unresectable HCC. However, TACE has several limitations itself which might be potentially associated with tumor metastasis and relapse.

Recent studies have demonstrated that arsenic trioxide (As2O3) can act as the first-line therapeutic option in the treatment of acute promyelocytic leukemia. Thereafter, several small studies in China showed promising clinical benefits when As2O3 is administrated among the HCC patients. With these preliminary results, the investigators are planning to carry out a multicenter randomized controlled trial through which to explore the potential efficacy and safety of adjuvant As2O3 treatment for HCC patients.

• Primary Hepatocellular Carcinoma

• TACE
• Arsenic trioxide

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

1. Subject is 18-80 years old.
2. Subject has no portal stem vein tumor thrombus.
3. Subject has primary middle-advanced liver cancer of Barcelona Clinic Liver Cancer stages B/C inappropriate for surgical resection or other locoregional therapy and still presents with tumor lesions in the liver.
4. Subject has evaluable tumor lesion(s) (using Magnetic Resonance Imaging /Computed Tomography) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) Version 1.1: single lesion size ≥5cm or at least one lesion of >3cm in size when 2-3 lesions exist or there are 4 or more lesions.
5. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status ≤1, Fibrosis index based on 4 factors (FIB-4)≤6 and an expected survival time of 12 weeks or more.
6. Haematology: white blood cell count ≥3.0×10^9/L; hemoglobin≥10 g/dL; blood platelet count≥80×10^9/L
7. Blood biochemistry: serum albumin ≥2.8 g/dL, total bilirubin ≤2 mg/dL or ≤34.2 umol/L, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2 times of upper limit of normal (ULN); amylase and lipase ≤ 1.5 times of ULN; serum creatinine ≤2.0 mg/dL or < 1.5 times of ULN; estimated creatinine clearance ≥60 mL/min.
8. International normalized ratio (INR) is ≤ 2.3 or prothrombin time (PT) is ≤3 seconds than upper limit of normal control.
9. Echocardiogram indicated a left ventricular ejection fraction (LVEF) of >50%.
10. Subject has a liver function Child-Pugh class A or B.
11. Subject is not pregnant or lactating.
12. Female subjects must be infertile or agree to take effective contraceptives; male subjects and their partners of reproductive potential must also agree to use appropriate contraceptives.
13. Subject had no second tumor in the last 5 years, excluding skin basal cell carcinoma or skin squamous carcinoma or any other carcinoma in situ.
14. Subject had no history of systemic chemotherapy.
15. Subject has no any other concomitant anticancer therapies, such as local radiotherapy, systemic chemotherapy and molecular targeted therapy.
16. Subject and (or) guardian is able to understand this study and willing to provide written, informed consent to participate in this clinical study.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

None (Open Label)

Lead Sponsor

Hunan Provincial People's HospitalOTHER

258600801@qq.com

liguowen@hnszlyy.com

ntdoctoryang@hotmail.com

huangming4328@sina.com

• Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC

  NCT02018757

  Unknown statusInterventionalPhase 2Updated May 28, 2014
• Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma

  NCT01861912

  Unknown statusInterventionalPhase 2Phase 3Updated Jun 5, 2013
• Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma

  NCT02585479

  WithdrawnInterventionalPhase 2Phase 3Updated Jun 4, 2019
• A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC

  NCT03116984

  Unknown statusInterventionalPhase 3Updated Apr 10, 2020
• Treatment of Intermediate-stage Hepatocellular Carcinoma

  NCT03274427

  Unknown statusInterventionalPhase 3Updated Sep 15, 2017
• Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas

  NCT01393093

  Unknown statusInterventionalNot ApplicableUpdated Jun 12, 2017